BIOMAT Database Logo BIOMAT Database Logo

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. 2022

Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Rigshospitalet, Department of Infectious Diseases, 2100 Copenhagen, Denmark.

HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

UI MeSH Term Description Entries

Related Publications

Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
July 2016, The Journal of antimicrobial chemotherapy,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
December 2013, Antimicrobial agents and chemotherapy,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
December 2011, The Journal of antimicrobial chemotherapy,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
November 2015, AIDS (London, England),
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
August 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
May 2022, The Journal of antimicrobial chemotherapy,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.
May 2018, The Journal of antimicrobial chemotherapy,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
March 2012, Journal of virology,
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
March 2014, AIDS (London, England),
Helene Mens, and Lasse Fjordside, and Jannik Fonager, and Jan Gerstoft
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
May 2023, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!